Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

Related Quality ◽

Health Related ◽

Over Time

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

American Journal of Hematology ◽

10.1002/ajh.25134 ◽

2018 ◽

Vol 93 (8) ◽

pp. 985-993 ◽

Cited By ~ 21

Author(s):

Xavier Leleu ◽

Tamas Masszi ◽

Nizar J. Bahlis ◽

Luisa Viterbo ◽

Bartrum Baker ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Phase Iii ◽

Health Related Quality ◽

Patient Reported ◽

Related Quality ◽

Health Related ◽

Reported Health

Faculty Opinions recommendation of Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969674.793470152 ◽

2013 ◽

Author(s):

Christopher Steer

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Phase Iii ◽

Newly Diagnosed ◽

Health Related Quality ◽

Phase Iii Trial ◽

Related Quality ◽

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study

Annals of Hematology ◽

10.1007/s00277-018-3469-4 ◽

2018 ◽

Vol 97 (12) ◽

pp. 2455-2463 ◽

Cited By ~ 7

Author(s):

David Cella ◽

Jan McKendrick ◽

Amber Kudlac ◽

Antonio Palumbo ◽

Abderrahim Oukessou ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Health Related Quality ◽

Related Quality ◽

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1747066 ◽

2020 ◽

Vol 61 (8) ◽

pp. 1850-1859

Author(s):

Katja Weisel ◽

Meletios Dimopoulos ◽

Philippe Moreau ◽

Munci Yagci ◽

Alessandra Larocca ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Low Dose ◽

Health Related Quality ◽

Phase 3 ◽

Related Quality ◽

Levels of Discordance Between Patients’ and Physicians’ Perceptions of Patients’ Health-Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM) – a Cross-Cultural Perspective

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2015.07.400 ◽

2015 ◽

Vol 15 ◽

pp. e176-e177

Author(s):

X. Leleu ◽

I.V. Broek ◽

C. Kyriakou ◽

P. Murphy ◽

P. Bacon ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Cross Cultural ◽

Health Related Quality ◽

Cultural Perspective ◽

Related Quality ◽

Effect of Treatment with Lenalidomide Plus Low-Dose Dexamethasone Until Progression on Health-Related Quality of Life Over Time in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.03.157 ◽

2017 ◽

Vol 17 (1) ◽

pp. e87

Author(s):

Dan T. Vogl ◽

Michel Delforge ◽

Kevin Song ◽

Shien Guo ◽

Craig J. Gibson ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Low Dose ◽

Newly Diagnosed ◽

Health Related Quality ◽

Related Quality ◽

Health Related ◽

Effect Of Treatment ◽

Over Time

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

Haematologica ◽

10.3324/haematol.2014.112557 ◽

2014 ◽

Vol 100 (2) ◽

pp. e63-e67 ◽

Cited By ~ 17

Author(s):

K. W. Song ◽

M. A. Dimopoulos ◽

K. C. Weisel ◽

P. Moreau ◽

A. Palumbo ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Low Dose ◽

High Dose ◽

Health Related Quality ◽

High Dose Dexamethasone ◽

Related Quality ◽

PF615 IMPACT OF PATIENTS CHARACTERISTICS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE CHARISMMA STUDY

HemaSphere ◽

10.1097/01.hs9.0000560748.69224.fa ◽

2019 ◽

Vol 3 (S1) ◽

pp. 261-262 ◽

Cited By ~ 1

Author(s):

L. Rosiñol ◽

E.M. Ocio ◽

M. Grande ◽

A. Fernandez-Nistal ◽

A. Ruiz-Zorrilla ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Health Related Quality ◽

Related Quality ◽

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Haematologica ◽

10.3324/haematol.2012.074534 ◽

2012 ◽

Vol 98 (5) ◽

pp. 784-788 ◽

Cited By ~ 45

Author(s):

M. A. Dimopoulos ◽

M. Delforge ◽

R. Hajek ◽

M. Kropff ◽

M. T. Petrucci ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Phase Iii ◽

Newly Diagnosed ◽

Health Related Quality ◽

Phase Iii Trial ◽

Related Quality ◽

Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

British Journal of Haematology ◽

10.1111/bjh.17435 ◽

2021 ◽

Author(s):

Torben Plesner ◽

Meletios A. Dimopoulos ◽

Albert Oriol ◽

Jesus San‐Miguel ◽

Nizar J. Bahlis ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Health Related Quality ◽

Phase 3 ◽

Related Quality ◽